Valproic Acid Antibody (Mouse Monoclonal)

<strong>Valproic Acid Antibody (Mouse Monoclonal)</strong> <table width="452"> <tbody> <tr> <td><strong>Catalog #</strong></td> <td>A2010004-7C8 A2010004-3B9 A2010004-9D1 A2010004-5C11 A2010004-6H7 A2010004-SET</td> </tr> <tr> <td><strong>Size</strong></td> <td>0.1 mg</td> </tr> <tr> <td><strong>Other Names</strong></td> <td>Mab to Valproic Acid, antibody to Valproic Acid</td> </tr> <tr> <td><strong>Host</strong></td> <td>Mouse</td> </tr> <tr> <td><strong>Concentration</strong></td> <td>1.0 mg/mL</td> </tr> <tr> <td><strong>Purity</strong></td> <td>&gt;90% (protein A column)</td> </tr> <tr> <td><strong>Storage</strong></td> <td>-20°C. Avoid repeated freeze/thaw cycles.</td> </tr> <tr> <td><strong>Supplied as</strong></td> <td>Liquid solution</td> </tr> <tr> <td><strong>Buffer</strong></td> <td>1X Phosphate Buffer Saline, pH 7.4 + 0.05% sodium azide.</td> </tr> <tr> <td><strong>Keywords</strong></td> <td>Valproic acid, mouse monoclonal antibody</td> </tr> </tbody> </table> &nbsp; <strong>References</strong> <ul> <li>Valproic acid enhances the viability of random pattern skin flaps: involvement of enhancing angiogenesis and inhibiting oxidative stress and apoptosis. <span class="labs-docsum-authors full-authors">Wu H, Ding J, Wang L, Lin J, Li S, Xiang G, Jiang L, Xu H, Gao W, Zhou K.</span> <span class="labs-docsum-journal-citation full-journal-citation">Drug Des Devel Ther. 2018 Nov 16;12:3951-3960. </span></li> <li>Valproicacid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.<span class="labs-docsum-authors full-authors"> Nau H, Hauck RS, Ehlers K.</span> <span class="labs-docsum-journal-citation full-journal-citation">Pharmacol Toxicol. 1991 Nov;69(5):310-21. </span></li> <li>Evaluation of the mood-stabilizing agent valproicacid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice.<span class="labs-docsum-authors full-authors"> Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS.</span> <span class="labs-docsum-journal-citation full-journal-citation">J Parasitol. 2008 Apr;94(2):555-7. </span></li> <li>Valproicacid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproicacid-induced neural tube defects.<span class="labs-docsum-authors full-authors"> Defoort EN, Kim PM, Winn LM.</span> <span class="labs-docsum-journal-citation full-journal-citation">Mol Pharmacol. 2006 Apr;69(4):1304-10. </span></li> <li>Derivatization oriented strategy for enhanced detection of valproicacid and its metabolites in human plasma and detection of valproicacid induced reactive oxygen species associated protein modifications by mass spectrometry.<span class="labs-docsum-authors full-authors"> Wu CY, Lu CY.</span> <span class="labs-docsum-journal-citation full-journal-citation">J Chromatogr A. 2014 Dec 29;1374:14-22.</span></li> <li>Acute valproicacid overdose. Clinical course and pharmacokinetic disposition of valproicacid and metabolites.<span class="labs-docsum-authors full-authors"> Dupuis RE, Lichtman SN, Pollack GM.</span> <span class="labs-docsum-journal-citation full-journal-citation">Drug Saf. 1990 Jan-Feb;5(1):65-71.</span></li> <li>Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study.<span class="labs-docsum-authors full-authors"> Amitai M, Sachs E, Zivony A, Remez R, Ben Baruch R, Amit BH, Kronenberg S, Apter A, Shoval G, Weizman A, Zalsman G.</span> <span class="labs-docsum-journal-citation full-journal-citation">Int <a href="https://pubmed.ncbi.nlm.nih.gov/26020713/">Clin Psychopharmacol.</a> 2015 Sep;30(5):241-8.</span></li> </ul>